Antengene (HKG:6996) First Half 2024 Results

Key Financial Results

• Net loss: CN¥167.0m (loss narrowed by 24% from 1H 2023).
• CN¥0.27 loss per share (improved from CN¥0.36 loss in 1H 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Antengene Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates by 21%.

Looking ahead, revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's shares are up 37% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 3 warning signs for Antengene you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.